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A B S T R A C T
Background: The role of the gut microbiome in the biotransformation of drugs has recently come under scru-
tiny. It remains unclear whether the gut microbiome directly influences the extent of drug absorbed after
oral administration and thus potentially alters clinical pharmacokinetics.
Methods: In this study, we evaluated whether changes in the gut microbiota of male Sprague Dawley rats, as a
result of either antibiotic or probiotic administration, influenced the oral bioavailability of two commonly
prescribed antipsychotics, olanzapine and risperidone.
Findings: The bioavailability of olanzapine, was significantly increased (1.8-fold) in rats that had undergone
antibiotic-induced depletion of gut microbiota, whereas the bioavailability of risperidone was unchanged.
There was no direct effect of microbiota depletion on the expression of major CYP450 enzymes involved in
the metabolism of either drug. However, the expression of UGT1A3 in the duodenum was significantly down-
regulated. The reduction in faecal enzymatic activity, observed during and after antibiotic administration, did
not alter the ex vivometabolism of olanzapine or risperidone. The relative abundance of Alistipes significantly
correlated with the AUC of olanzapine but not risperidone.
Interpretation: Alistipes may play a role in the observed alterations in olanzapine pharmacokinetics. The gut
microbiome might be an important variable determining the systemic bioavailability of orally administered
olanzapine. Additional research exploring the potential implication of the gut microbiota on the clinical phar-
macokinetics of olanzapine in humans is warranted.
Funding: This research is supported by APC Microbiome Ireland, a research centre funded by Science Founda-
tion Ireland (SFI), through the Irish Government’s National Development Plan (grant no. 12/RC/2273 P2) and
by Nature Research-Yakult (The Global Grants for Gut Health; Ref No. 626891).










A growing body of evidence supports the role of the gut micro-
biota in dictating the fate and activity of drugs [1,2]. In recent times,
the ability of the gut microbiota to directly metabolise drugs, and
consequently influence drug pharmacokinetics and clinical outcomes,
has come under increasing scrutiny [2,3]. Classically, the influence of
the gut microbiome on drug pharmacokinetics was mostly limited to
bacterial metabolism of drug metabolites excreted via the bile into
the intestine (for example, glucuronide conjugates) leading to pro-
longation of drug half-life, or as commonly referred to the enterohe-
patic recirculation. More recently, studies have highlighted how the
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enzymes; GF, germ-free; HPLC, High performance liquid chromatography; I.S., internal
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risperidone; RT-qPCR, reverse-transcriptase quantitative polymerase chain reaction;
5-HT, Serotonin (5-hydroxytryptamine); 5-HT-GLU, Serotonin β-D-Glucuronide;
Tmax, time taken to reach maximum plasma concentration; UGT, Uridine 5′-diphos-
pho-glucuronosyltransferase
(**Point of contact for correspondence during review and processing of the manuscript).
* Corresponding authors at: School of Pharmacy, University College Cork, College
Road, Cork City, Ireland.
E-mail addresses: j.cryan@ucc.ie (J.F. Cryan), brendan.griffin@ucc.ie (B.T. Griffin).
1 Equal Contributions.
https://doi.org/10.1016/j.ebiom.2021.103307
2352-3964/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
EBioMedicine 66 (2021) 103307
Contents lists available at ScienceDirect
EBioMedicine
journal homepage: www.elsevier.com/locate/ebiom
microbiome may directly metabolise a variety of drugs and how the
metabolic activity of the microbiome can both activate or degrade
drugs [4]. The microbiome can also produce metabolites which com-
pete with drugs for drug-metabolising enzymes or can modulate the
latter’s gene expression [2,5]. While the metabolic capacity of the
microbiome to metabolise a diverse array of drugs is clear, what
remains unclear is the extent to which this significantly impacts clini-
cal pharmacokinetics of drugs in vivo (i.e.,>20% change in systemic
drug concentrations) [6]. Similarly, changes in the gut microbiome
have been increasingly reported as a potential source of inter-indi-
vidual variability, but a limited number of studies have explored
whether changes in gut microbiome can lead to clinically significant
changes to in vivo pharmacokinetics.
Previous work from our laboratory has linked the gut microbiome
to alterations in drug pharmacodynamics; antibiotic-induced micro-
biota depletion attenuated olanzapine (OLZ)-associated metabolic
dysfunction in rats [7,8]. This is consistent with studies in germ-free
(GF) mice who do not gain weight following oral administration of
OLZ [9]. Although the mechanistic basis for this association remains
unclear, most attention has been placed on the antimicrobial effects
of OLZ [9,10]. Microbiota depletion is considered a crucial factor in
the reduction of metabolic side effects associated with this drug. A
similar role of the gut microbiome in risperidone (RISP)-associated
metabolic side effects has also been suggested [11], and a recent
meta-analysis of both animal and human studies linked antipsy-
chotic-induced metabolic dysfunction to the gut microbiome [12].
This study aimed to extend this research further to assess whether
perturbations to the gut microbiome could also alter the pharmacoki-
netic profile of these two antipsychotic drugs.
OLZ and RISP are both centrally active, poorly water-soluble
drugs, according to pharmacopoeial specifications, with comparable
half-lives, and are widely used clinically (see Table 1). Although both
are associated with microbiome-mediated weight gain in vivo [7,11],
and antimicrobial effects in vitro [9,10], they exhibit some differences
in pharmacokinetic profiles, chemical structure and microbiota expo-
sure. OLZ is cleared primarily via hepatic metabolism, with less than
10% of the drug excreted unchanged in the urine [13], and 30%
detected in faecal material [14,15]. The cytochrome-P450 (CYP) sys-
tem metabolises OLZ, principally by CYP1A2, and to a lesser extent by
CYP2D6. OLZ displays a substantial first-pass effect, with ~40% of the
oral dose subject to pre-systemic metabolism. OLZ is also subject to
glucuronidation via phase II enzymes UDP-glucuronosyltransferase
(UGT) 1A4 and to a lesser extent, UGT2B10. In the case of RISP,
CYP2D6-mediated metabolism to form 9-hydroxyrisperidone is con-
sidered the major metabolic pathway in humans; CYP3A4 also plays a
minor role in the generation of this active metabolite [16]. RISP
undergoes little to no phase II hepatic metabolism, and most of the
oral dose, approximately 70%, is recovered unchanged in the urine
[16,17].
The primary objective of this study was to assess whether pertur-
bations to the gut microbiota would influence the oral bioavailability
of either OLZ or RISP. Two models of microbiota-targeted interven-
tions in rats were explored: one rat group received an antibiotic cock-
tail over two weeks to deplete the microbiota, and a second group
received a commercially available cocktail of probiotics (VSL#3) over
the same period. The impact of these microbiota-directed interven-
tions on the oral bioavailability of both drugs was subsequently com-
pared to control rats.
2. Methods
2.1. Animals
Adult male Sprague Dawley rats (n = 67/group; 200250 g on
arrival) were obtained from Envigo UK. Based on our experience in
employing these microbiota-targeted intervention animal models
coupled with results from published comparative bioavailability
studies, the following statistical parameters were employed in
powering this study design: the power (1-b) of the study set as 80%,
calculations based on an effect size of 1.33 (estimated from previous
studies with similar experimental design), with the significance level
(a) set as 5%. These calculations were performed on G*Power (version
3.1.9.2 University Kiel, Germany). Under these conditions, a total
sample size of 67 was determined necessary to achieve significance
for comparisons. They were housed 34 per standard cage in a con-
ventional animal facility and maintained under a 12 h light/dark
cycle, provided with chow and water ad libitum. Animals were ran-
domly assigned to different cohorts using a random number genera-
tor. Rats in the same cage underwent the same treatment to avoid
confounding factors such as a coprophagic effect. Animals were accli-
mated to housing conditions for one week before the experimental
treatment.
2.2. Ethics
Animal experiments comply with the ARRIVE guidelines and
were carried out in accordance with the U.K. Animals (Scientific
Procedures) Act, 1986, and associated guideline European Direc-
tive 2010/63/EU. Approval by the Animal Experimentation Ethics
Committee of University College Cork (AE19130/P049) was
obtained before the commencement of all animal-related experi-
ments. The body weight of each rat was regularly monitored
every three days to assess weight-loss induced by probiotic or
antibiotic treatment.
Research in context
Evidence before this study
Despite the growing evidence of a relationship between drugs
and the gut microbiome, pharmacokinetic studies illustrating
the potential clinical significance of such findings are still lack-
ing. Yoo and colleagues have previously shown antibiotic-
induced microbiota depletion can alter the absorption or
metabolism of lovastatin, aspirin, and amlodipine and also that
supplementation with the probiotic strain Lactobacillus reuteri
reduced the bioavailability of acetaminophen possibly linked to
the modulation of the metabolic activity of the gut microbiota.
Added value of this study
The study herein investigates if perturbations to the gut micro-
biota, induced by an antibiotic or probiotic mix, can translate to
altered pharmacokinetics of olanzapine or risperidone in rats.
This is the first pharmacokinetic study, to our knowledge, to
explore microbiota-mediated metabolism of CNS-active drugs.
Given that antibiotic-induced microbiota depletion precipitated
a 1.8-fold increase in olanzapine bioavailability, several differ-
ent mechanisms governing gut-microbiota-drug interactions
were investigated. Interestingly, the microbiota-targeted inter-
ventions did not alter the pharmacokinetics of risperidone, sug-
gesting the impact of microbiota depletion may be drug-
specific.
Implications of all the available evidence
The results suggest that sources of variability in the composi-
tion and function of the gut microbiota may need to be consid-
ered a potential cause of altered drug pharmacokinetics and,
ultimately, patient response to certain drugs.
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2.3. Antibiotic and probiotic treatment
Antibiotics or probiotics were administered for 14 days in the
drinking water. The antibiotic cocktail consisted of ampicillin 1 g/L,
vancomycin 500 mg/L, and imipenem 250 mg/L [adapted from [20]],
and the solution was freshly prepared every second day. The probiot-
ics consisted of VSL#3, a commercially available multi-strain prepara-
tion, which was administered in a dose of 51010 bacteria/kg/day
[21]. VSL#3 contains four strains of lactobacilli (Lactobacillus paraca-
sei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus),
three strains of bifidobacteria (Bifidobacterium longum, B. breve and B.
infantis) and Streptococcus salivarius subsp. Thermophiles. The probi-
otic solution was prepared daily just before the start of the dark cycle
(Fig. 1a).
2.4. Antipsychotic administration and sample collection
The two-week pre-treatment with either vehicle, probiotics or
antibiotics, was followed with a 24 h intervention-free period to limit
any drug-antibiotic or -probiotic interactions. After the 24 h period
elapsed, a single dose of OLZ (20 mg/kg) or RISP (15 mg/kg), sus-
pended in 0.1% v/v methylcellulose, was administered to the rats via
Table 1
Overview of the physiochemical properties of the antipsychotics.
Drug name, IUPAC name, and structure Dosage Physiochemical properties
Mol.wt. Log P pKa Solubility (H2O)
Olanzapine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno [2,3b] [1,5]benzodiazepine
Target: 10 mg/day 312 g/mol 2 7.37a 0.039 mg/ml
Risperidone
3- [2- [4-(6-fluoro-1,2-benzoxazol-3-yl) piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-pyrido [1,2-a]
pyrimidin-4-one
Range: 210 mg/day 410 g/mol 3.49 8.24a 0.064 mg/mlb
Log P: partition co-efficient;
a [18];
b [19]
Fig. 1. Experimental timeline, body weight, and caecum weight. (a) Experimental timeline. (b) Neither probiotic nor antibiotic administration influence the body weight gain. (c)
Antibiotic administration increases caecum weight (KW p = 0.000, U = 0, p = 0.000). Caecum weight is expressed as median + min-to-max values. *p < 0.05 (n = 1314/group).
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oral gavage. Following administration of the antipsychotics, whole
blood samples were collected into heparinized tubes from the tip of
the tail at different timepoints (30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h).
The plasma was harvested by centrifugation at 3000 g for 10 min and
stored at 20 °C until further analysis. Tissue samples from the liver
(frontal lobe), caecum, duodenum, and colon were also taken at dis-
section and immediately snap-frozen. At dissection, caecal content
was also isolated from the caecum and stored separately. Faecal sam-
ples were collected periodically during the pre-treatment period. All
samples were kept at 80 °C until further analysis.
2.5. High performance liquid chromatography (HPLC) detection of the
drugs in plasma and caecal contents
The liquid-liquid extraction (LLE) protocol and HPLC conditions
employed for the detection of OLZ and RISP in plasma samples was
based on previously published methods with some modifications
[22,23]. Detailed information on plasma and caecum preparation, as
well as drug extraction, is presented in the Supplemental Methods.
The accuracy of the technique was determined by carrying out the
extraction procedure on plasma or caecal content samples spiked
with known concentrations of the drug of interest, followed by HPLC
analysis. For analyte identification and quantification, calibration
standards were prepared by spiking 10 or 20 ml of working standard
solutions (RISP or OLZ) into 90 ml of blank rat plasma or 200 ml of
blank rat caecal contents respectively at final concentrations of
15.62000 ng/ml. Calibration curves were generated by plotting the
[peak area of analyte versus internal standard (I.S.); OLZ], or analyte
peak area (RISP), versus the concentration of the analyte using least-
square linear regression. The correlation coefficients of the calibra-
tion curves were greater than 0.94. The percentage coefficient of vari-
ation (% CV) for the HPLC method, assessed over five days, was less
than 16% for both drugs. Further information on the HPLC equipment
is detailed in the Supplemental Methods.
2.6. Pharmacokinetic analysis
The maximum plasma concentration (Cmax) and the time taken
to reach Cmax (Tmax) for OLZ and RISP were estimated directly from
the plasma concentration-time profiles. Pharmacokinetic parameters,
including the area under the plasma drug curve (AUC), clearance (Cl),
and mean residual time (MRT), were all calculated using a non-com-
partmental model. The AUC was calculated using the linear trapezoi-
dal method from the first to the last measured plasma concentration,
i.e., AUC0-8h. Antipsychotic drug clearance from plasma was esti-
mated by dividing AUC by the administered drug dose, and MRT was
calculated by dividing AUC0-8h by the area under the first-moment
curve (AUMC0-8h). Each point in the PK curve represents the average
of seven independent samples (n = 7/experimental group/drug), apart
from the OLZ 1h time-point only where plasma samples were har-
vested from 3 rats (n = 3). The reduced numbers at this specific time-
point arose due to difficulties in obtaining free-flowing blood from
the tail of certain rats. As a safety and welfare precaution, we decided
to not apply any undue pressure to the tail to minimise the amount
of stress inflicted to these animals and jeopardise the collection of
later time-points. The OLZ or RISP concentration in each individual
plasma sample was calculated based on the average of duplicate
readings.
2.7. Microbiota composition of the caecal content
DNA was extracted from the caecal content using the Qiagen
QIAmp Fast DNA Stool Mini Kit coupled with an initial bead-beating
step. The V3-V4 hypervariable region of the 16S rRNA gene was
amplified and prepared for sequencing as outlined in the Illumina
16S Metagenomic Sequencing Library protocol. Samples were
sequenced at the Teagasc Sequencing Facility (TFRC, Moorepark) on
the Illumina MiSeq platform using a 2 £ 250 bp kit. Reads were
assembled, processed and analysed following the pipeline described
in Supplemental Methods.
2.8. RNA extractions, reverse transcription, and quantitative RT-qPCR
Total RNA was extracted from the intestinal tissue and the front
lobe of the liver with the mirVanaTM miRNA isolation kit (Thermo
Fisher Scientific/Ambion) following the manufacturer’s protocol. A
Nanodrop 1000 (Thermo Scientific, UK) was used to determine RNA
concentration. RNA was reverse transcribed using a high capacity
cDNA reverse transcription kit (Thermo Fisher Scientific/Applied Bio-
systems) in a G-storm thermocycler (G-storm, Surrey, UK). Genes of
interest (listed in the Supplemental Methods) were amplified using
SYBR Green primers. Each transcript value was calculated as the aver-
age of triplicate samples across experimental conditions. Values were
normalized to b-actin or GAPDH. Data were analysed with the com-
parative cycle threshold method (2DDCt) [24], and presented as a
fold change vs vehicle group.
2.9. Protein extractions and Western blots
Total proteins from liver samples were extracted through sonica-
tion, BCA quantification (Thermo Fisher Scientific), and heat denatur-
ation. Protein levels were detected on SDS-page gels using
appropriate primary antibody dilutions against CYP1A2 (1:5000;
Abcam ab22717), CYP2D1 (1:1000; Enzo BML-CR3210), CYP3A1
(1:1000; Millipore AB1253), UGT1A (1:500; Santa Cruz sc-271268),
secondary antibody HRP-conjugated to rabbit or mouse (1:10000;
Thermo Fisher Scientific). For CYP1A2, CYP2D1 and CYP3A1, the con-
trol for protein loading consisted of b-actin (1:1000; Santa Cruz, sc-
47778). For UGT1A the control for protein loading consisted of ERK1/
2 (1:1000; Cell Signaling #9102). Quantification of protein bands was
performed using ImageJ software, and protein levels were normal-
ized to the loading control and presented as fold change relative to
the vehicle group. Significance was determined by a one-way ANOVA
followed by Dunnett’s test.
2.10. Fecalase: preparation and enzymatic assay
Fecalase, the enzyme fraction of faeces [25], was prepared from
approximately 70 mg fresh-frozen rat faeces collected on day 12 of
the 14-day pre-treatment period, according to a modified method
previously described [26]. Briefly, the faecal pellet was suspended in
1 mL potassium phosphate buffer (0.01M, pH7.4) and homogenised
using a mini Bead-Beater machine for 1.5 min. The faecal suspension
was centrifuged at 2000 rpm for 5 min, and the resulting supernatant
was centrifuged at 10,000 rpm for 20 min. The supernatant isolated
after the second centrifugation step (fecalase) was then used for the
assay of enzyme activity.
For quantification of enzymatic activity, the reaction mixture, con-
taining 50ml fecalase, 100ml potassium phosphate buffer (0.01M, pH
7.4) and 100 ml 4-nitrophenyl-b-D-glucopyranoside (1 mM, Sigma
Aldrich) for b-glucosidase or 100 ml 4-nitrophenyl-b-D-glucuronide
(1 mM, Sigma Aldrich) for b-glucuronidase, was incubated at 37 °C
for 15 min. After incubation, 250 ml NaOH (0.5 N) was added to stop
the reaction, and the absorbance was measured at 405 nm (UVvis
spectrophotometer). The Pierce BCA Protein Assay Kit (ThermoFisher
Scientific) was used, following the kit protocol, to measure the total
protein concentration in the fecalase samples. Enzyme activity was
indicated as the amount required to catalyse the formation of 1mmol
of p-nitrophenol per minute under the standard assay conditions.
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2.11. Fecalase: ex vivo incubation with OLZ, RISP, and Serotonin b-D-
Glucuronide (positive control)
To assess whether either OLZ or RISP was subject to bacterial-
derived enzymatic degradation, the drug was incubated with fecalase
prepared from vehicle-, probiotic- and antibiotic-treated rats. The
reaction mixture, containing 50 ml fecalase, 200 ml potassium phos-
phate buffer (0.01M, pH 7.4) and 50 ml OLZ or RISP (0.25 mM, in
DMSO), was prepared in duplicate and incubated with agitation
(450 rpm) at 37 °C for 48 h. As experimental controls, a fecalase-only
reaction mix [50 ml fecalase and 250 ml potassium phosphate buffer
(0.01M, pH 7.4)] and drug-only reaction mix [50 ml OLZ or RISP
(0.25 mM, in DMSO) and 250 ml potassium phosphate buffer (0.01M,
pH 7.4); in triplicate] were also prepared and incubated simulta-
neously to the experimental samples. Aliquots (60 ml) were taken at
T0, T24, and T48 from each sample. Methanol was added to each ali-
quot (1:1) to stop the reaction. The amount of remaining OLZ or RISP
was then determined using HPLC-UV. Peak areas of OLZ and RISP
were normalised to the drug-only control of each corresponding day
of incubation.
Previous research has illustrated the glucuronide metabolite of
the monoamine neurotransmitter serotonin, serotonin b-D-Glucu-
ronide (5-HT-GLU), is subject to deconjugation by bacterial-
derived b glucuronidase [27]. As a positive control, 5-HT-GLU
was incubated using the same reaction mix as outlined above
with some modifications. Each reaction mix was maintained at
37 °C for one hour (from T0 to T1), as per a previous method
[27]. After an aliquot was taken at T0 and T1, the reaction was
stopped with MeOH (1:1). Before HPLC-ECD analysis, an equal
volume of I.S. (n-methyl 5-HT, 2 ng/20 ml in HPLC mobile phase)
was added to each sample and vortex-mixed. The total volume
(300 ml) was then transferred to the HPLC vial, and 20 ml of the
final sample was injected onto the column for analysis. The
method for the HPLC-ECD quantification of the parent compound
5-HT was based on our previously published method [28].
2.12. Statistics
All datasets were checked for normality (Shapiro-Wilk test)
and homogeneity (Levene’s test). Data that satisfied both homo-
geneity and normality tests were analysed using one-way ANOVA
followed by Dunnett’s test. The corresponding data are presented
as mean + SEM and include the following datasets: body weight,
AUC bar plots, duodenal and hepatic gene expression, hepatic
protein levels and fecalase readout. The plasma pharmacokinetic
curves and parameters (Fig. 4ac) are presented as mean + SD to
clearly illustrate subject variability. In order to explore differences
in the drug concentrations over time, a repeated measures
ANOVA was also performed in conjunction with Tukey’s multiple
comparisons test. Datasets that did not satisfy the assumptions of
homogeneity and normality were analysed using the Kruskal-
Wallis non-parametric test followed by Mann-Whitney test and
corrected for multiple comparisons using the Benjamin-Hochberg
false discovery rate (FDR) method. These datasets (caecum weight
and microbiota genera) are presented as median and min-to-max
values. Spearman’s correlation coefficient was employed for the
analysis of associations between pharmacokinetic parameters and
bacterial taxa abundance. Grubbs method was employed to test
for any specific outliers [29]. The threshold for statistical signifi-
cance was set at p < 0.05.
2.13. Role of funding source
The funders had no role in study design, data collection, data anal-
ysis, interpretation or writing of the report.
3. Results
3.1. Microbiota-targeted interventions did not significantly alter body
weight
Over the two-week administration of either antibiotic or probiotic
cocktails, rat body weight was monitored daily. There were no differ-
ences observed between control (i.e., vehicle-treated rats) and probi-
otic- or antibiotic-treated animals (Fig. 1b). Upon cessation of the
study and collection of organs, the caecum weight was significantly
increased in antibiotic-treated rats (Fig. 1c).
3.2. Antibiotics and probiotics differentially impacted the caecal
microbiota composition
To assess the impact of the microbiota-targeted interventions, 16S
sequencing of bacterial rRNA was performed on the caecum content.
As expected, the sequencing revealed a significant decrease in the
bacterial richness and diversity of rats treated with antibiotics as
compared to the control group (Fig. 2b). Moreover, separation by
group was further illustrated through principal coordinate analysis
(PCoA), with statistical support of the significant separation between
the antibiotic and the vehicle group (p < 0.001, Fig. 2c). The marked
difference between the antibiotic and the control group was also
detected at the genus level, with several genera being depleted in the
antibiotic group (Fig. 2a). The phylum and family microbiome signa-
tures were also significantly disrupted by antibiotics (Fig. S1). In pro-
biotic-treated rats, no marked differences were evident at the genus
level, alpha, or beta diversity (Fig. 2).
Previous research from our group and others has shown that psy-
chotropic drugs can influence the composition of the gut microbiota
[30,31]. To assess whether a single dose of OLZ or RISP would impact
the microbiome per se, we checked the alpha diversity in the vehicle
group, and no significant differences were detected between OLZ-
and RISP-treated rats (Fig. 2b).
At the phylum and family level, several bacteria were altered by
both microbiome-targeted interventions (Figure S1, Tables S1, and
S2), with antibiotics causing a depletion in several families. At the
genus level, antibiotics induced a broad depletion, while the genera
Anaeroplasma was significantly increased in antibiotic-treated rats
and Lachnospiraceae UCG006 was increased but not significantly
(Fig. 3, Table S3). The three bacterial strains present in the VSL#3 pro-
biotic formulation belong to the genera Lactobacillus, Streptococcus,
and Bifidobacterium. Among these three taxa, only Streptococcus was
significantly increased in the caecum of probiotic-treated rats com-
pared to vehicle-treated rats. Other taxa that were significantly
increased in probiotic-treated rats included Erysipelatoclostridium,
Marvinbryantia, and Odoribacter (Fig. 3).
3.3. Antibiotic-induced depletion of gut microbiota influenced the oral
bioavailability of OLZ
The plasma concentration levels of OLZ and RISP were determined
after oral administration to the vehicle-, probiotic- and antibiotic-
treated animals. The plasma concentration-time profile and AUC of
OLZ are shown (Fig. 4a). The resultant pharmacokinetic parameters
are also described in Fig. 4c. Antibiotic-induced microbiota depletion
significantly increased the AUC0-8h of OLZ by approximately 82% after
a single oral dose. Probiotic treatment had no impact on the pharma-
cokinetics of OLZ. In the case of RISP, neither of the microbiome-
directed interventions significantly influenced its oral bioavailability
(Fig. 4b).
In order to further explore differences in the profile of the drug
concentrations over time, a repeated measure ANOVA was per-
formed. OLZ plasma concentrations were significantly higher after
antibiotics, relative to vehicle, at the 1.5 h and 4 h time-points (OLZ:
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ABX vs vehicle; p < 0.05 at both time-points). This is in line with the
overall PK difference in terms of total AUC. In the case of RISP, a sig-
nificant difference in plasma concentrations was found at the 6h
time-point (RISP: ABX vs vehicle; p < 0.05 at 6 h). The magnitude of
the difference at 6 h, however, appears to be relatively small and
given the lack of a difference in total AUC, the potential impact of this
effect is, thus, considered minor.
3.4. AUC correlated with the relative abundance of the genera Alistipes
in OLZ- but not RISP-treated rats
After demonstrating that changes in the microbiome occurred in
parallel with changes in the systemic absorption of OLZ (Fig. 4a), we
compared whether the relative abundance of specific taxa was asso-
ciated with pharmacokinetic parameters [including AUC0-8h, Cmax,
Tmax, and CL] in both antipsychotic-receiving groups. In OLZ-treated
rats, the relative abundance of Alistipes negatively and significantly
correlated with AUC (Fig. 5). This correlation was not observed in
RISP-treated rats. All other taxa, including Bifidobacterium, did not
show significant correlations with pharmacokinetic-related parame-
ters after adjusting for multiple testing (Fig. 5).
3.5. Neither intervention altered the levels of CYPs involved in the
metabolism of antipsychotics
To test whether the probiotics or antibiotics had any direct
effect on the hepatic expression of CYP enzymes relevant for the
metabolism of antipsychotics, RT-qPCR was employed to examine
the CYP gene expression at the transcript level. Interspecies com-
parison of CYPs isoforms present in rats and humans have been
previously described (Fig. 6a) [32]. Neither the probiotic nor anti-
biotic treatment altered the hepatic mRNA expression of the rat-
equivalent human isoenzymes implicated in the metabolism of
OLZ and RISP (Fig. 6a). To further confirm the transcript findings
at the protein level, Western blotting analysis of the same CYPs
was performed. As shown in Fig. 6a, there was no difference in
CYP1A2 or CYP2D1 protein in the livers of probiotic- and antibi-
otic-treated rats. Conversely, both microbiota-targeted interven-
tions significantly upregulated CYP3A1 protein, the magnitude of
the effect more substantial in the case of the antibiotic-treated
rats (p < 0.001 vs probiotic p < 0.05). As CYP3A1 is, however,
only a minor metaboliser of RISP, the significance of this finding
is somewhat limited.
Fig. 2. Caecum microbiota composition (16S sequencing). (a) Bar charts representing the taxa abundance at the genus level. The 20 most abundant taxa are shown. (b) Alpha
diversity. KruskalWallis test for Chao1 (p = 0.000) and Shannon (p = 0.000). MannWhitney U test for Chao1 and Shannon: antibiotic p < 0.001 compared to vehicle. Data are
expressed as median + min-to-max values. Samples are rarefied to read depth of 32817. (c) Beta diversity, principal coordinate analysis of Bray-Curtis compiled distance matrix of
all microbial relative abundances compared to the vehicle group. Antibiotic animals show significant variation from the vehicle (Adonis PERMANOVA p < 0.001, R2 = 0.764), inde-
pendent of drug treatment. (n = 67/group).
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3.6. Neither microbiota-targeted intervention altered duodenal
expression of tight junctions andMDR-1A
Previous studies have suggested that antibiotic administration
can induce a dysregulation in intestinal barrier function [33,34],
and the presence of the gut microbiota is important to maintain
normal barrier function. For this reason, we assessed the gene
expression of two key tight junctions, occludin and zonula occlu-
dens-1 (ZO-1) in the duodenum, the main site of absorption of
xenobiotics. This was carried out to exclude the possibility that
an antibiotic-induced barrier dysfunction in the duodenum might
be responsible for the increased absorption of OLZ in the circula-
tion. Neither probiotics nor antibiotics induced changes in the
expression of tight junctions (Fig. 6b). The gene expression of
multidrug resistance protein 1a (MDR-1a), a major efflux trans-
porter in the intestinal lumen, was also assessed. The isoform 1a
was selected in the duodenum because of its widespread distribu-
tion in this tissue compared to the isoform 1b [35]. Neither of the
microbiota-targeted interventions, however, altered the expres-
sion of MDR-1a in the duodenum (Fig. 6b).
3.7. Antibiotic-induced microbiota depletion altered intestinal
glucuronidation gene expression but not hepatic MDR-1A gene
expression
While OLZ undergoes an extensive first-pass effect, the major
metabolic pathway involved in this first-pass effect is unclear. We
aimed to assess if phase II metabolism, or possibly first-pass metabo-
lism through UGT could be a contributory factor to the increased sys-
temic absorption of OLZ in antibiotic-treated rats. There is limited
evidence comparing species differences of UGT isoforms in rats and
humans, especially in terms of substrate specificity. We, therefore,
measured the transcript levels of UGT2B3 and UGT1A3 in the duode-
num and liver, as surrogate rat isoforms predicted to be the most
similar to the human 2B10 and 1A4, respectively [36]. In the liver,
antibiotics increased both UGT isoforms, while probiotics signifi-
cantly increased the transcript levels of UGT2B3 (Fig. 7a). None of the
microbiota-targeted interventions, however, altered the expression
of MDR-1a in the liver (Fig. 7b). In the duodenum, probiotic intake
increased UGT2B3 and decreased UGT1A3; while antibiotics reduced
the transcript levels of UGT1A3 (Fig. 7c). In addition, the protein levels
of UGT1A were quantified both in the liver and in the duodenum
(Fig. S3). Neither of the microbiota-targeted interventions signifi-
cantly influenced the protein levels of the enzymatic family UGT1A at
both body sites.
3.8. OLZ and RISP were not subject to fecalase-mediated metabolism
Fecalase, the enzyme fraction (i.e. cell free extract) of faeces
[25], can be used as an ex vivo metabolism assay to study the
metabolic activity of the gut microbiota, as well as xenobiotic
metabolism by the intestinal bacteria. This strategy has previously
elucidated the role of the gut microbiota in the metabolism of
lovastatin, aspirin, and amlodipine. In this study, the activity of
two microbial-derived enzymes was investigated as a surrogate
readout of the metabolic activity of the gut microbiota. Antibi-
otic-induced microbiota depletion markedly decreased the
expression of b-glucuronidase faecal enzymatic activity by the
end of antibiotic treatment. This reduced b-glucuronidase activity
was confirmed based on a significant reduction in the conversion
of 5-HT-GLU to the parent compound, 5-HT, in antibiotic-treated
rats relative to vehicle-treated rats. (Fig. 8a). Both microbiota-tar-
geted interventions significantly reduced b-glucosidase activity
relative to vehicle-only rats (Fig. S2b).
Fig. 3. Probiotics and antibiotics differentially affect bacterial composition at the genus level. Many bacterial genera are completely depleted in antibiotic-treated rats. The
genus Anaeroplasma is significantly increased in antibiotic-treated rats. Lachnospiraceae UCG006 is also increased but not significantly in antibiotic-treated rats. Streptococcus, Erysi-
pelatoclostridium, Marvinbryantia, and Odoribacter are significantly increased in probiotic-treated rats compared to the vehicle group. Data are expressed as median + min-to-max
values *p < 0.05 VS vehicle, #p < 0.05 VS vehicle (n = 1314/group). Data was analysed using Kruskal-Wallis non-parametric test followed by Mann-Whitney U test and corrected
for multiple comparisons using the Benjamin-Hochberg false discovery rate (pFDR) method (refer to Supplemental Material for details on statistics).
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The probiotic treatment did not elicit a similar effect in b-glucu-
ronidase. It is, therefore, tempting to speculate if different bacterial
strains may express these enzymes. At this juncture, having shown
the fecalase assay can successfully illustrate fecalase-mediated
metabolism, the next step was to assess if OLZ or RISP were also sub-
ject to fecalase-mediated degradation. OLZ and RISP were incubated
with fecalase from the vehicle-, probiotic- and antibiotic-treated rats
for 48 h, and HPLC was used to estimate the remaining amount of the
drug. Our data revealed that neither drug was degraded by fecalase
(Fig. 8b).
4. Discussion
Pharmacomicrobiomics is an emerging field that explores the
effects of microbiome variations on drug pharmacokinetics and
pharmacodynamics [37,38]. While the vast metabolic capacity of the
microbiome to metabolise a diverse array of drugs is clear, what
remains unexplored is the extent to which changes in the micro-
biome can result in clinically significant changes in systemic drug lev-
els.
In this study, two microbiota-targeted interventions were
employed to assess whether the pharmacokinetic profile of two com-
monly prescribed antipsychotics, OLZ and RISP, might be influenced
by changes in the microbiome. Our data reveal that the bioavailability
of OLZ was increased 82% after a single oral dose following antibiotic-
induced microbiome depletion, and provides evidence that the gut
microbiome may play a role in modulating the oral bioavailability of
OLZ. In contrast, the bioavailability of RISP was not influenced by
microbiome perturbations. The study herein investigated several
mechanisms through which the microbiota may influence the
Fig. 4. Pharmacokinetic profile of OLZ and RISP after oral administration in rats pre-treated with the vehicle, probiotic or antibiotic. (a) Plasma levels and area under the
curve (AUC) of OLZ. Following a 24 h break, OLZ (20 mg/kg) was orally administered to rats pre-treated with vehicle, probiotic or antibiotic for 14 days (n = 7/group, n = 3 @1 h time-
point). The AUC of OLZ is increased by antibiotic administration (One-way ANOVA F(2;20)=3.58, p < 0.05; t-test p = 0.033). (b) Plasma levels and AUC of RISP. Following a 24 h break,
RISP (15 mg/kg) was orally administered to rats pre-treated with vehicle, probiotic or antibiotic for 14 days (n = 67/group). (c) Pharmacokinetic parameters of OLZ and RISP after
oral administration in rats pre-treated with vehicle, probiotic or antibiotic. Each point in the PK curve represents the average of 7 independent samples (n = 7/experimental group/
drug), apart from the OLZ 1.5h time-point where plasma samples were harvested only from 3 rats (n = 3). The OLZ or RISP concentration in each individual plasma sample was calcu-
lated based on the average of duplicate readings. Bar plots are expressed as mean + SEM; graphs over time are expressed as mean + SD.
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metabolism or absorption of OLZ. We hypothesised that OLZ may be
directly metabolised by bacterial-derived enzymes or indirectly
affected by microbiome-induced changes on host metabolism. Given
the short half-life of the selected antibiotics and a 24 h wash out
period before drug dosing, the risk of a carryover antibiotic effect on
inhibiting host metabolism is considered minimal. The unchanged
pharmacokinetics of RISP supports this rationale. Moreover, while
certain antibiotics can induce host metabolic enzymes, we specifi-
cally chose those that have not been shown in literature to exert this
effect. The most plausible explanation for the 1.8-fold increase in the
systemic exposure to olanzapine in the microbiome-depleted group
is a reduction in the first pass metabolism of this drug, linked to
downregulation of duodenal UGT expression.
The gut microbiota has been previously linked to changes in the
expression of phase I hepatic metabolism [39]. Neither the probiotic
nor the antibiotic cocktail altered the hepatic expression of CYP1A2
and CYP2D1 implicated in the host metabolism of OLZ and RISP both
at transcript and protein level (Fig. 6). The protein expression of
CYP3A1, which was significantly increased in antibiotic-treated rats,
has been previously increased by macrolide antibiotics in both rat
and human hepatocytes [40]. CYP3A1, however, only plays a minor
role in the metabolism of antipsychotics. Our results suggest there-
fore that the changes in pharmacokinetics following antibiotic treat-
ment is not due to a direct inhibition of phase I hepatic pathways.
VSL#3 administration did not impact the pharmacokinetics of either
antipsychotic. Future studies employing different dosages and time-
courses of the multi-strain probiotic cocktail, or examining each pro-
biotic strain individually, are warranted.
First-pass intestinal- and liver-mediated metabolism can have an
extensive impact on the bioavailability of UGT substrates in humans
[41]. Glucuronidation via UGT1A4, and to a lesser extent UGT2B10, is
the primary mode of OLZ metabolism; an effect that differentiates
OLZ from RISP. Moreover, polymorphisms in these enzymes have
been previously suggested as a potential source of inter-individual
variability in OLZ metabolism and therapeutic response [42].
Interestingly, the activities of UGT1A3 and UGT1A4 can show up to
60-fold variation between individuals, increasing clinical risks such
as significant variations of plasma concentrations and subsequent
toxicity [43]. Hence, there remains an unmet need to identify the
potential key drivers of this variability to guide and assist clinical dos-
age regulation in personalised medicine. The in vivo contribution of
intestinal and hepatic glucuronidation in rats has been previously
described in the literature, albeit a relatively unexplored area in pre-
clinical research in comparison to the vast knowledge on human
metabolism [44]. Nonetheless, the differential expression of UGT by
antibiotic-induced microbiota depletion was investigated as a poten-
tial mechanistic explanation for the increased OLZ bioavailability.
The significant downregulation of the UGT1A4 equivalent isoform
(UGT1A3) in the duodenum of antibiotic-treated rats hints at the
potential for the microbiota to play a role in glucuronidation medi-
ated by the intestine. Decreased metabolism of OLZ by the gastroin-
testinal enterocytes may hence be responsible for the increased
levels of the drug reaching the systemic circulation. While pre-treat-
ment with probiotics also significantly decreased the expression of
UGT1A3, the accompanying probiotic-associated upregulation of the
UGT2B10 equivalent rat isoform (UGT2B3) may act as a compensatory
metabolic route. In contrast to the duodenum, antibiotic-induced
microbiota depletion significantly upregulated hepatic UGT expres-
sion (Fig. 7b). The higher expression of UGT1A3 in the duodenum of
rats in comparison to the liver may, however, limit the significance of
this finding [36]. Neither microbiota manipulation induced a signifi-
cant effect on the protein levels of the enzyme UGT1A in the duode-
num and liver (Fig. S3). These results must be interpreted with
caution, as there is some inconsistency in the literature regarding the
relationship between protein levels and functional enzymatic activity
[45]. In cases where protein levels do not match the transcript levels,
several factors could be responsible for this discrepancy, including
protein stability, post-transcriptional regulations and degradation
rate of the mRNA [46]. In addition, previous studies in humans have
reported not only a divergence between UGT1A mRNA and protein
Fig. 5. Spearman correlations between AUC and the relative abundance of two bacteria in OLZ- and RISP-treated rats. (a) In OLZ-treated rats, AUC significantly correlates with
the relative abundance of Alistipes (p = 0.002245, adj p = 0.045, r = 0.64); n = 21. Bifidobacterium does not correlate with AUC. (b) In RISP-treated rats, no significant correlations
are observed between AUC and bacterial abundance; n = 20. Data are normalized and CLR-transformed. ns = not significant.
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Fig. 6. The impact of microbiota-targeted interventions on hepatic and duodenal genes. (a) Gene expression and protein levels of relevant CYPs in the liver. The literature-iden-
tified rat CYP enzymes equivalent to human CYPs implicated in the metabolism of OLZ and RISP are illustrated. Probiotic and antibiotic administration do not alter the gene expres-
sion and protein levels of CYP1A2 and CYP2D1 compared to the vehicle group. Both probiotics and antibiotics increase the protein levels of CYP3A1 (One-way ANOVA F(2;19)=19.25,
p< 0.001; post-hoc p = 0.049 for probiotic vs vehicle, p = 0.000 for antibiotic vs vehicle) without altering gene expression. The protein bands of two representative samples per group
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levels [4749], but also a high degree of variability in UGT mRNA and
protein expression within different tissues and different individuals
[47,50]. In addition, considering the wide range of isoforms detected
from the antibody UGT1A, a microbiota-mediated effect on the iso-
form 1A3 cannot be completely ruled out. Due to the inter-species
differences in glucuronidation, and the limited evidence of specific
rat UGT enzymes implicated in the metabolism of OLZ, care must be
exercised in the interpretation and extrapolation of the results to
humans [51].
Evidence suggests that antibiotics can induce a barrier dysfunc-
tion in the GI tract [33,34]. With increased levels of OLZ in the blood
of antibiotic-treated rats, a disruption in intestinal permeability
might have been the cause of an increased absorption at the duode-
num level. However, according to the gene expression of two tight
junction proteins, occludin and ZO-1, antibiotics did not alter duode-
nal permeability.
To elucidate whether bacterial-derived enzymes could directly
metabolise OLZ, we next utilised fecalase as an ex vivo screening plat-
form for gut microbiota-mediated drug metabolism. Antibiotic treat-
ment significantly depleted the enzymatic activity of two microbial
enzymes, with the activity of b-glucuronidase falling to levels below
the limit of detection of the assay (Fig. 8a). The suppressed metabolic
activity significantly reduced the deconjugation of 5-HT-GLU to 5-HT
after brief exposure to fecalase (i.e., 1 h incubation). This reduced
metabolic activity, however, did not translate to altered metabolism
of OLZ even after incubation for a total of 48 h (Fig. 8b). Suppression
of the metabolic activity of the gut microbiota has been previously
linked to increased bioavailability of both aspirin and amlodipine in
rats pre-treated with a single dose of ampicillin [52,53]. In both stud-
ies, fecalase from antibiotic-treated rats reduced the formation of a
drug metabolite. Thus, the fecalase-mediated metabolism of OLZ
could be further investigated as a potential mechanism by comparing
the formation rate of OLZ metabolites in fecalase from antibiotic-
treated rats versus vehicle-only rats. Further studies could continue
to investigate the direct microbial metabolism of OLZ by testing the
hypothesis that fecalase, specifically the microbial-derived enzyme
b-glucuronidase, could convert a glucuronide-conjugated metabolite
of OLZ (OLZ 10-N glucuronide or OLZ 4-N glucuronide) into the par-
ent compound through a similar ex vivo incubation assay. Further-
more, OLZ may be subject to bacterial-mediated metabolism higher
up the rat intestinal region, albeit an area associated with lower
microbial colonisation. A crude enzymatic fraction isolated from the
upper small intestine has been previously investigated for the probi-
otic-mediated metabolism of acetaminophen [54].
Across 156 genera detected by 16S sequencing, Alistipes only cor-
related with the bioavailability (i.e., AUC) of OLZ- but not RISP-treated
Fig. 7. Hepatic gene expression of UGTs and MDR-1a and duodenal gene expression of UGTs. (a) Both probiotics and antibiotics increase the hepatic gene expression of UGT2B3
(One-way ANOVA F(2;20)=13.14, p < 0.001; post-hoc p < 0.01 for probiotic vs vehicle and p < 0.001 for antibiotic vs vehicle). Antibiotics increase the hepatic gene expression of
UGT1A3 (One-way ANOVA F(2;20)=67.33, p < 0.001; post-hoc p < 0.001). *p < 0.05, **p < 0.05, ***p < 0.001. Data are expressed as mean + SEM (n = 67/group). (b) Both probiotics
and antibiotics do not affect the hepatic gene expression of MDR-1a. Data are expressed as mean + SEM (n = 67/group). (c) Probiotic administration increases the duodenal gene
expression of UGT2B3 (One-way ANOVA F(2;19)=10.37, p < 0.01; post-hoc p < 0.05). Both probiotics and antibiotics decrease the duodenal gene expression of UGT1A3 (One-way
ANOVA F(2;19)=53.79, p < 0.001; post-hoc p < 0.001 for both groups vs vehicle). Data are expressed as mean + SEM (n = 67/group).
are shown. Data are expressed as mean + SEM *p < 0.05, ***p< 0.001, ns=not significant (n = 57/group). (b) Gene expression of relevant tight junctions and MDR in the duodenum.
No significant differences are noted across groups. Data are expressed as mean + SEM (n = 57/group).
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rats, suggesting that this specific bacterium may play a role in the
pharmacokinetic alterations of OLZ. Intriguingly, the genus Alistipes
has been previously linked to patient response to chemotherapy.
Specifically, the abundance of Alistipes correlated positively with the
immunotherapy-induced production of TNF in conventional mice
[55]. Administration of an antibiotic cocktail (vancomycin, imipenem,
and neomycin in drinking water) significantly disrupted the micro-
biome, impaired immunotherapy efficacy, and, therefore, TNF pro-
duction [55]. Moreover, Alistipes indistinctus (DSM 22520) was
recently identified as one bacterial strain linked to the chemical mod-
ification of approximately 40 drugs; half of these substrate drugs
were greater than 80% metabolised [4]. Interestingly, the authors
showed greater than 50% of RISP was metabolised after 12 h incuba-
tion with this bacterial strain. Our data, however, did not find an
association between RISP and Alistipes. Although the evidence on the
role played by specific taxa on drug response is still limited, the
research by Iida, and Zimmermann, and colleagues’ sheds light upon
the potential role of Alistipes in drug efficacy.
The results of this initial proof-of-concept study proposes that
antibiotic-depletion of olanzapine glucuronidation on first pass
through the small intestine as the plausible mechanism underpinning
the 1.8-fold increase in olanzapine bioavailability. Further unravel-
ling the mechanistic basis behind the overall impact of microbiota
depletion on drug pharmacology is, however, warranted and may
provide valuable insight in this field. A follow-on study where these
antipsychotics are administered intravenously could offer a strategy
to bypass intestinal first-pass metabolism and clarify the magnitude
of the antibiotic-induced microbiota depletion on drug absorption.
This study is not, however, without limitations. The expression and
protein levels of host metabolic genes were determined using whole
liver or duodenal samples, whereas specific microsomal expression
would provide further insights. The activity of b-glucuronidase and
b-glucosidase enzymes was studied primarily as a surrogate readout
of the metabolic activity of the gut microbiota; we cannot discount
that other bacterial enzymes may play a direct role in OLZ metabo-
lism. The identification of specific enzymes implicated in the metabo-
lism of OLZ and RISP, and the impact of these microbiota-targeted
interventions on such enzymes, is warranted.
While this study suggests that chronic antibiotic use may lead to
elevated olanzapine levels, a complex relationship between drug
pharmacokinetics and pharmacodynamics exists. As mentioned, our
previous research illustrated antibiotic-induced depletion of the gut
microbiota can dissipate the metabolic side-effects associated with
OLZ, an effect that could be presumed contrary to these pharmacoki-
netic results. While the 1.8-fold increase in the systemic availability
of OLZ may increase the risk of dose-limiting side-effects, including
somnolence and dizziness and metabolic dysfunction [56,57], the
overall clinical relevance may be dependent on specific patient-
related factors including age, hepatic function and concomitantly
taken medication. Nonetheless, elevated OLZ levels have been linked
to an increased risk of developing diabetes, peripheral oedema and
postural hypotension and warrant consideration in clinical practice
[58]. Clinically, antibiotic-related interactions with OLZ have, thus
far, been linked to the direct inhibition of CYP1A2; the co-
Fig. 8. Fecalase-mediated metabolism. (a) Antibiotic-induced depletion of b-glucuronidase activity translates to altered deconjugation of 5-HT-GLU. Antibiotics downregulate
b-glucuronidase enzymatic activity in fecalase (vs vehicle; p < 0.0001). The conversion of 5-HT-GLU to the parent compound, 5-HT, is significantly decreased in fecalase prepared
from antibiotic-treated vs vehicle-treated rats (One-way ANOVA, p < 0.05). Probiotics do not alter the b-glucuronidase activity or the rate of deconjugation of 5-HT-GLU. Data are
expressed as mean + SEM *p < 0.05 ***p < 0.001 (n = 910 for enzymatic readout; n = 7 for 5-HT-HPLC data). (b) Ex vivo incubation of OLZ and RISP with fecalase. The amount of
remaining OLZ and RISP is not altered after 48 h incubation with fecalase from antibiotic- and probiotic-treated rats compared to vehicle-treated rats. Data are expressed as
mean + SEM, relative to the drug-only incubation controls (n = 67/group).
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prescription of ciprofloxacin may necessitate a reduction in OLZ dos-
age to minimize adverse effects. The results herein provide further
scope to consider the impact of antibiotic-induced effects on OLZ
therapy.
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